602 related articles for article (PubMed ID: 8863700)
21. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K; Nicolaides KH
Prenat Diagn; 2002 Oct; 22(10):877-9. PubMed ID: 12378569
[TBL] [Abstract][Full Text] [Related]
22. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
23. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
24. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
25. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
26. [Results of prenatal screening for fetal chromosome abnormality during the first trimester pregnancy in Guangzhou].
Xu Z; Li B; Liao C; Sun Q; Bai X; Li D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):632-5. PubMed ID: 25297598
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Dhaifalah I; Májek O
Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss.
Goetzl L; Krantz D; Simpson JL; Silver RK; Zachary JM; Pergament E; Platt LD; Mahoney MJ; Wapner RJ
Obstet Gynecol; 2004 Jul; 104(1):30-6. PubMed ID: 15228997
[TBL] [Abstract][Full Text] [Related]
29. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K; Ong CY; Liao AW; Papademetriou D; Nicolaides KH
Prenat Diagn; 2000 Aug; 20(8):673-5. PubMed ID: 10951481
[TBL] [Abstract][Full Text] [Related]
30. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K; Ong C; Skentou H; Liao AW; H Nicolaides K
Prenat Diagn; 2000 May; 20(5):411-6. PubMed ID: 10820411
[TBL] [Abstract][Full Text] [Related]
31. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
32. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
[TBL] [Abstract][Full Text] [Related]
33. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
34. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
[TBL] [Abstract][Full Text] [Related]
35. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.
Santorum M; Wright D; Syngelaki A; Karagioti N; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):714-720. PubMed ID: 27549925
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.
Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST
Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021
[TBL] [Abstract][Full Text] [Related]
38. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center.
Alamillo CM; Krantz D; Evans M; Fiddler M; Pergament E
Prenat Diagn; 2013 Mar; 33(3):251-6. PubMed ID: 23354915
[TBL] [Abstract][Full Text] [Related]
39. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
40. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy.
Nicolaides KH; Brizot ML; Snijders RJ
Br J Obstet Gynaecol; 1994 Sep; 101(9):782-6. PubMed ID: 7947527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
